Atrial Fibrillation Management in Elderly

被引：0
作者：
Aronow W.S. [1 ,2 ,3 ]
机构：
[1] Westchester Medical Center/New York Medical College, Valhalla, NY
[2] Cardiology Division, Department of Medicine, New York Medical College, Valhalla, NY
[3] Cardiology Division, New York Medical College, Macy Pavilion, 138, Valhalla, NY
来源：
Current Cardiovascular Risk Reports | 2012年 / 6卷 / 5期
关键词：
Antiarrhythmic drugs; Anticoagulant therapy; Apixaban; Aspirin; Atrial fibrillation; Beta blockers; Cardioversion; Clopidogrel; Dabigatran; Pacemakers; Radiofrequency catheter ablation; Rivaroxaban; Thromboembolism; Ventricular rate control; Warfarin;
D O I：
10.1007/s12170-012-0263-z
中图分类号：
学科分类号：
摘要：
Atrial fibrillation (AF) in older adults is inherently more clinically challenging than sinus rhythm because it is associated with diminished functional capacity and quality of life, as well as higher incidence of mortality, stroke, and coronary events. AF with a rapid ventricular rate is particularly likely to cause demand ischemia, heart failure with preserved ejection fraction (HFPEF), as well as tachycardia-related cardiomyopathy. Indications for direct-current cardioversion, pharmacological cardioversion, rate control, and nondrug therapies are discussed. Differences in clinical outcome based on ventricular rate control versus drug treatment to maintain sinus rhythm are also reviewed. Indications for anticoagulation for chronic or paroxysmal AF are included, including long-term warfarin and direct thrombin inhibitors (dabigatran, rivaroxaban, or apixaban) and/or aspirin. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：431 / 442
页数：11
相关论文
共 101 条
  • [1] Pollak, A., Falk, R.H., Pacemaker therapy in patients with atrial fibrillation (1993) Am Heart J., 125, pp. 824-830
  • [2] Aronow, W.S., Use of beta-adrenergic blockers in antiarrhythmic therapy (1986) Practical Cardiol., 12 (6), pp. 75-89
  • [3] Abrams, J., Allen, J., Allin, D., Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial (1985) Am Heart J, 110, pp. 913-922
  • [4] Salerno, D.M., Dias, V.C., Kleiger, R.E., Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter (1989) Am J Cardiol., 63, pp. 1046-1051
  • [5] Aronow, W.S., Landa, D., Plasencia, G., Verapamil in atrial fibrillation and atrial flutter (1979) Clin Pharmacol Therap., 26, pp. 578-583
  • [6] Falk, R.H., Knowlton, A.A., Bernard, S.A., Digoxin for converting recent onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial (1987) Ann Intern Med., 106, pp. 503-506
  • [7] Aronow, W.S., Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients: which is the preferred treatment? (1991) Drugs Aging., 1, pp. 98-103
  • [8] David, D., Segni, E.D., Klein, H.O., Kaplinsky, E., Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent (1979) Am J Cardiol., 44, pp. 1378-1382
  • [9] Roth, A., Harrison, E., Milani, G., Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation (1986) Circulation., 73, pp. 316-324
  • [10] Lang, R., Klein, H.O., Weiss, E., Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation (1983) Chest., 83, pp. 491-499
12345678910